<p>Shattuck Labs, Inc.（納斯達克代碼：STTK - 獲取免費報告）在覆蓋該股票的六家券商中獲得了 “適度買入” 的共識評級，Marketbeat.com 報道。一位投資分析師給予該股票賣出評級，兩位給予持有評級，兩位給予買入評級，還有一位給予強烈買入評級。在過去一年中，發佈報告的券商對該股票的平均一年目標價為 3.00 美元。</p>
<p>STTK 最近成為多份分析師報告的主題。Needham &amp; Company LLC 在 8 月 14 日的研究報告中重新發布了對 Shattuck Labs 股票的 “持有” 評級。華爾街禪在 9 月 13 日的報告中將 Shattuck Labs 的評級從 “賣出” 上調至 “持有”。Leerink Partners 在 8 月 14 日的研究報告中將 Shattuck Labs 的目標價從 4.00 美元下調至 2.00 美元，並對該股票設定了 “跑贏大盤” 的評級。Weiss Ratings 在 10 月 8 日的報告中重新發布了對 Shattuck Labs 股票的 “賣出（d-）” 評級。最後，Wedbush 在 9 月 8 日的研究報告中開始覆蓋 Shattuck Labs 股票。他們對該公司的評級為 “跑贏大盤”，目標價為 4.00 美元。</p>
<p>獲取 <strong>Shattuck Labs</strong> 的提醒：</p>
<p><strong>查看我們對 STTK 的最新分析</strong></p>
<h2>Shattuck Labs 股價上漲 5.2%</h2>
<p>納斯達克 STTK 週五開盤價為 2.03 美元。Shattuck Labs 的一年低點為 0.69 美元，一年高點為 2.71 美元。該公司的 50 日移動平均價為 2.06 美元，200 日移動平均價為 1.37 美元。該公司的市值為 1.2846 億美元，市盈率為-1.99，貝塔值為 1.88。</p>
<p>Shattuck Labs（納斯達克：STTK - 獲取免費報告）最近一次公佈財報是在 11 月 6 日，報告顯示該季度每股收益為（0.14）美元，超出市場共識預期的（0.15）美元 0.01 美元。該季度的營業收入為 100 萬美元。分析師平均預測 Shattuck Labs 本年度每股收益為-1.48 美元。</p>
<h2>Shattuck Labs 的內部活動</h2>
<p>在相關消息中，董事 Mona Ashiya 於 8 月 25 日購買了 6,306,127 股該股票，交易發生在該日。股票的平均購買價格為每股 0.87 美元，總價值為 5,486,330.49 美元。收購完成後，該董事直接持有該公司 5,255,106 股，價值約為 4,571,942.22 美元。此交易代表其持股比例增加了 600.00%。該收購在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。此外，董事 Orbimed Advisors Llc 也於 8 月 25 日購買了 6,306,127 股該公司的股票，平均購買價格為每股 0.87 美元，總價值為 5,486,330.49 美元。交易完成後，該董事直接持有該公司 5,255,106 股，價值為 4,571,942.22 美元。此交易同樣代表其持股比例增加了 600.00%。該購買的 SEC 文件提供了更多信息。12.00% 的股票由公司內部人士持有。</p>
<h2>對 Shattuck Labs 的對沖基金看法</h2>
<p>幾家大型投資者最近對 STTK 的持倉進行了調整。Turtle Creek Wealth Advisors LLC 在第三季度獲得了 Shattuck Labs 的新頭寸，價值約為 29,000 美元。Virtu Financial LLC 在第三季度獲得了 Shattuck Labs 的新頭寸，價值 38,000 美元。AQR Capital Management LLC 在第一季度將其在 Shattuck Labs 的持倉增加了 265.4%。AQR Capital Management LLC 目前持有該公司 43,169 股股票，價值 41,000 美元，此前在該期間內又購買了 31,355 股。Qube Research &amp; Technologies Ltd 在第二季度獲得了 Shattuck Labs 的新頭寸，價值約為 44,000 美元。最後，Squarepoint Ops LLC 在第三季度獲得了 Shattuck Labs 的新頭寸，價值 46,000 美元。機構投資者和對沖基金持有該公司 58.74% 的股票。</p>
<h2>關於 Shattuck Labs</h2>
<p>（獲取免費報告）</p>
<p>Shattuck Labs, Inc. 是一家臨牀階段的生物技術公司，專注於開發用於治療癌症和自身免疫疾病的療法。該公司的主要產品候選藥物是 SL-172154，目前正在進行卵巢癌、輸卵管癌和腹膜癌的第一階段臨牀試驗。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Shattuck Labs</li>
<li>3 只 REIT 值得長期投資</li>
<li>一項偉大的 AI 投資？Stanley Druckenmiller 最新的科技動態</li>
<li>股息貴族的最佳名單：通過貴族指數積累財富</li>
<li>12 位分析師剛剛提高了 CrowdStrike 的目標價——他們預見了什麼</li>
<li>金融服務股票投資</li>
<li>Palo Alto Networks 股票剛剛回調——這是一個理想的買入區嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RUSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RUSw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Shattuck Labs 嗎？</h2>
<p>在考慮 Shattuck Labs 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Shattuck Labs 並不在名單上。</p>
<p>雖然 Shattuck Labs 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

STTK

<p>Shattuck Labs, Inc.（納斯達克代碼：STTK）獲得了六家券商的共識 “適度買入” 評級。分析師的意見各不相同，評級範圍從賣出到強烈買入不等。平均目標價格為 3.00 美元。近期內部人士的購買和對沖基金的活動表明市場對該股票的興趣。Shattuck Labs 是一家臨牀階段的生物技術公司，專注於癌症和自身免疫治療，其主要候選藥物正在進行第一階段臨牀試驗</p>

<p>Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) has earned a consensus rating of &#34;Moderate Buy&#34; from the six brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $3.00.</p>
<div class="lb-trans"><p>Shattuck Labs, Inc.（納斯達克代碼：STTK - 獲取免費報告）在覆蓋該股票的六家券商中獲得了 “適度買入” 的共識評級，Marketbeat.com 報道。一位投資分析師給予該股票賣出評級，兩位給予持有評級，兩位給予買入評級，還有一位給予強烈買入評級。在過去一年中，發佈報告的券商對該股票的平均一年目標價為 3.00 美元。</p>
</div><p>STTK has been the topic of a number of recent analyst reports. Needham &amp; Company LLC reissued a &#34;hold&#34; rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Wall Street Zen raised Shattuck Labs from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, September 13th. Leerink Partners reduced their price target on shares of Shattuck Labs from $4.00 to $2.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, August 14th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Shattuck Labs in a report on Wednesday, October 8th. Finally, Wedbush assumed coverage on shares of Shattuck Labs in a research report on Monday, September 8th. They issued an &#34;outperform&#34; rating and a $4.00 price objective for the company.</p>
<div class="lb-trans"><p>STTK 最近成為多份分析師報告的主題。Needham &amp; Company LLC 在 8 月 14 日的研究報告中重新發布了對 Shattuck Labs 股票的 “持有” 評級。華爾街禪在 9 月 13 日的報告中將 Shattuck Labs 的評級從 “賣出” 上調至 “持有”。Leerink Partners 在 8 月 14 日的研究報告中將 Shattuck Labs 的目標價從 4.00 美元下調至 2.00 美元，並對該股票設定了 “跑贏大盤” 的評級。Weiss Ratings 在 10 月 8 日的報告中重新發布了對 Shattuck Labs 股票的 “賣出（d-）” 評級。最後，Wedbush 在 9 月 8 日的研究報告中開始覆蓋 Shattuck Labs 股票。他們對該公司的評級為 “跑贏大盤”，目標價為 4.00 美元。</p>
</div><p>Get <strong>Shattuck Labs</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Shattuck Labs</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Analysis on STTK</strong></p>
<div class="lb-trans"><p><strong>查看我們對 STTK 的最新分析</strong></p>
</div><h2>Shattuck Labs Trading Up 5.2%</h2>
<div class="lb-trans"><h2>Shattuck Labs 股價上漲 5.2%</h2>
</div><p>NASDAQ STTK opened at $2.03 on Friday. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $2.71. The company has a 50 day moving average of $2.06 and a 200-day moving average of $1.37. The firm has a market cap of $128.46 million, a price-to-earnings ratio of -1.99 and a beta of 1.88.</p>
<div class="lb-trans"><p>納斯達克 STTK 週五開盤價為 2.03 美元。Shattuck Labs 的一年低點為 0.69 美元，一年高點為 2.71 美元。該公司的 50 日移動平均價為 2.06 美元，200 日移動平均價為 1.37 美元。該公司的市值為 1.2846 億美元，市盈率為-1.99，貝塔值為 1.88。</p>
</div><p>Shattuck Labs (NASDAQ:STTK - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. The business had revenue of $1.00 million during the quarter. On average, analysts forecast that Shattuck Labs will post -1.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>Shattuck Labs（納斯達克：STTK - 獲取免費報告）最近一次公佈財報是在 11 月 6 日，報告顯示該季度每股收益為（0.14）美元，超出市場共識預期的（0.15）美元 0.01 美元。該季度的營業收入為 100 萬美元。分析師平均預測 Shattuck Labs 本年度每股收益為-1.48 美元。</p>
</div><h2>Insider Activity at Shattuck Labs</h2>
<div class="lb-trans"><h2>Shattuck Labs 的內部活動</h2>
</div><p>In related news, Director Mona Ashiya purchased 6,306,127 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the completion of the acquisition, the director directly owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their position. The acquisition was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, Director Orbimed Advisors Llc acquired 6,306,127 shares of the company's stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the transaction, the director directly owned 5,255,106 shares in the company, valued at $4,571,942.22. The trade was a -600.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 12.00% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Mona Ashiya 於 8 月 25 日購買了 6,306,127 股該股票，交易發生在該日。股票的平均購買價格為每股 0.87 美元，總價值為 5,486,330.49 美元。收購完成後，該董事直接持有該公司 5,255,106 股，價值約為 4,571,942.22 美元。此交易代表其持股比例增加了 600.00%。該收購在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。此外，董事 Orbimed Advisors Llc 也於 8 月 25 日購買了 6,306,127 股該公司的股票，平均購買價格為每股 0.87 美元，總價值為 5,486,330.49 美元。交易完成後，該董事直接持有該公司 5,255,106 股，價值為 4,571,942.22 美元。此交易同樣代表其持股比例增加了 600.00%。該購買的 SEC 文件提供了更多信息。12.00% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Shattuck Labs</h2>
<div class="lb-trans"><h2>對 Shattuck Labs 的對沖基金看法</h2>
</div><p>Several large investors have recently made changes to their positions in STTK. Turtle Creek Wealth Advisors LLC acquired a new position in Shattuck Labs in the third quarter valued at approximately $29,000. Virtu Financial LLC acquired a new position in Shattuck Labs in the 3rd quarter worth $38,000. AQR Capital Management LLC boosted its position in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock worth $41,000 after buying an additional 31,355 shares during the period. Qube Research &amp; Technologies Ltd acquired a new position in Shattuck Labs during the 2nd quarter worth approximately $44,000. Finally, Squarepoint Ops LLC acquired a new position in Shattuck Labs during the third quarter worth $46,000. Institutional investors and hedge funds own 58.74% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近對 STTK 的持倉進行了調整。Turtle Creek Wealth Advisors LLC 在第三季度獲得了 Shattuck Labs 的新頭寸，價值約為 29,000 美元。Virtu Financial LLC 在第三季度獲得了 Shattuck Labs 的新頭寸，價值 38,000 美元。AQR Capital Management LLC 在第一季度將其在 Shattuck Labs 的持倉增加了 265.4%。AQR Capital Management LLC 目前持有該公司 43,169 股股票，價值 41,000 美元，此前在該期間內又購買了 31,355 股。Qube Research &amp; Technologies Ltd 在第二季度獲得了 Shattuck Labs 的新頭寸，價值約為 44,000 美元。最後，Squarepoint Ops LLC 在第三季度獲得了 Shattuck Labs 的新頭寸，價值 46,000 美元。機構投資者和對沖基金持有該公司 58.74% 的股票。</p>
</div><h2>About Shattuck Labs</h2>
<div class="lb-trans"><h2>關於 Shattuck Labs</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.</p>
<div class="lb-trans"><p>Shattuck Labs, Inc. 是一家臨牀階段的生物技術公司，專注於開發用於治療癌症和自身免疫疾病的療法。該公司的主要產品候選藥物是 SL-172154，目前正在進行卵巢癌、輸卵管癌和腹膜癌的第一階段臨牀試驗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Shattuck Labs</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>Financial Services Stocks Investing</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Shattuck Labs</li>
<li>3 只 REIT 值得長期投資</li>
<li>一項偉大的 AI 投資？Stanley Druckenmiller 最新的科技動態</li>
<li>股息貴族的最佳名單：通過貴族指數積累財富</li>
<li>12 位分析師剛剛提高了 CrowdStrike 的目標價——他們預見了什麼</li>
<li>金融服務股票投資</li>
<li>Palo Alto Networks 股票剛剛回調——這是一個理想的買入區嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RUSw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=STTK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Shattuck Labs Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Shattuck Labs 嗎？</h2>
</div><p>Before you consider Shattuck Labs, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Shattuck Labs 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shattuck Labs wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Shattuck Labs 並不在名單上。</p>
</div><p>While Shattuck Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Shattuck Labs 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Shattuck Labs, Inc.（NASDAQ:STTK）被分析師一致推薦為 “適度買入”